Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: Significance and therapy response

Medical and Pediatric Oncology

Volumn 39, Issue 6, 2002, Pages 558-565

  Attarbaschi, Andishe ^a   Mann, Georg ^a   Dworzak, Michael ^a   Wiesbauer, Peter ^a   Schrappe, Martin ^b   Gadner, Helmut ^a  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Chemotherapy intensification; Chemotherapy response; Mediastinal mass; Prognosis; T lineage ALL

Indexed keywords

ANTINEOPLASTIC AGENT; PREDNISONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; AUSTRIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CANCER SURGERY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; MULTICENTER STUDY; PRIORITY JOURNAL; PROGNOSIS; T CELL LEUKEMIA; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INFANT; LEUKEMIA, T-CELL, ACUTE; MALE; MEDIASTINAL NEOPLASMS; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0036887815     PISSN: 00981532     EISSN: None     Source Type: Journal    
DOI: 10.1002/mpo.10164     Document Type: Article

References (31)

1. Pui CH, Behm FG, Crist WM. Clinical and biological relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood 1993;82:343-362.
2. Greaves MF, Janossy G, Peto J, et al. Immunologically defined subclasses of acute lymphoblastic leukemia in children: Their relationship to presentation features and prognosis. Br J Haematol 1981;48:179-197.
3. Pullen DJ, Boyett JM, Crist WM, et al. Pediatric Oncology Group utilization of immunologic markers in the designation of acute lymphocytic leukemia subgroups: Influence on treatment response. Ann NY Acad Sci 1984;428:26-48.
4. Crist WM, Shuster JJ, Look T, et al. Current results of studies of immunophenotype-, age-, and leukocyte-based therapy for children with acute lymphoblastic leukemia. A Pediatric Oncology Group study. Leukemia 1992;6:162-167.
5. Riehm H, Reiter A, Schrappe M, et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83). Klin Pädiatr 1986;199:151-160.
6. Uckun FM, Reaman G, Steinherz PG, et al. Improved clinical outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: A Children's Cancer Group study. Leuk Lymphoma 1996;24:57-70.
7. Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735-746.
8. Pullen DJ, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T-cell acute lymphoblastic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. Leukemia 1999;13:1696-1707.
9. Reiter A, Schrappe M, Ludwig W-D, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133.
10. Schorin MA, Blattner St, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-747.
11. Nachman J, Sather HN, Gaynon PS, et al. Augmented Berlin-Frankfurt-Münster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: A report from the Children's Cancer Group. J Clin Oncol 1997;15:2222-2230.
12. Schrappe M, Reiter A, Ludwig W-D, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000;95:3310-3322.
13. Amylon MD, Shuster JJ, Pullen DJ, et al. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T-cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: A Pediatric Oncology Group study. Leukemia 1999;13:335-342.
14. Shikano T, Arioka H, Kobayashi R, et al. Acute lymphoblastic leukemia and non-Hodgkin's Lymphoma with mediastinal mass - A study of 23 children, different disorders or different stages? Leuk Lymphoma 1994;13:161-167.
15. Chilcote RR, Coccia P, Sather HN, et al. Mediastinal mass in acute lymphoblastic leukemia. Med Pediatr Oncol 1984;12:9-16.
16. Reiter A, Schrappe M, Ludwig WD, et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: A BFM Group report. Blood 2000;95:416-421.
17. Sheperd SF, A'Hern RP, Pinkerton CR, on behalf of the United Kingdom Children's Cancer Study group (UKCCSG). Childhood T- cell lymphoblastic lymphoma - Does early resolution of mediastinal mass predict for final outcome? Br J Cancer 1995;72:752-756.
18. Ravindranath Y, Kaplan J, Zuelzer WW, et al. Significance of mediastinal mass in acute lymphoblastic leukemia. Pediatrics 1975;55:889-893.
19. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extra-medullary disease and T-cell phenotype or other poor prognostic features. Cancer 1998;82:600-612.
20. Pui C-H, Behm FG, Singh B, et al. Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. Blood 1990;75:174-179.
21. Pullen DJ, Sullivan MP, Falletta JM, et al. Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell Leukemia: Results and prognostic factors (A Pediatric Oncology Group study). Blood 1982;60:1159-1168.
22. Shuster JJ, Falletta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: A Pediatric Oncology Group study. Blood 1990;75:166-173.
23. Garand R, Vannier JP, Béné MC, et al. Comparison of outcome, clinical, laboratory, and immunological features in 164 children and adults with T-ALL. Leukemia 1990;4:739-744.
24. Gadner H, Krepler P, Kummer M, et al. Kooperative Therapiestudien der kindlichen akuten lymphatischen Leukämie (ALL) in Österreich-Erfahrungsbericht nach 10 Jahren. Wien Klin Wochenschr 1985;97:140-148.
25. Gruemayer ER, Gadner H, Mutz I, et al. Childhood acute lymphoblastic leukemia: Results of the Austrian Cooperative Study Group with the ALL A 84 protocol. Med Pediatr Oncol 1990;18:6-14.
26. Bennet JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukemias. French- American-British (FAB) cooperative group. Br J Haematol 1976;33:451-458.
27. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
28. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50:163-170.
29. Israel O, Front D, Lam M, et al. Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer 1988;61:2439-2443.
30. Bayar E, Prasad M, Rama J, et al. Anterior mediastinal mass in childhood non-Hodgkin's lymphoma: Dilemma of post-therapy imaging. Med Pediatr Oncol 2000;34:157-161.
31. Bangerter M, Kotzerke J, Griesshammer M, et al. Positron emission tomography with 18-Fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol 1999;38:799-804.